Ramipril belongs to the angiotensin II converting enzyme inhibitors class of anti-hypertensives. This class of drugs prevents the constriction of the blood vessels by stopping the conversion process from Angiotensin I to Angiotensin II. ACE inhibitors reduce albuminuria more than other BP-lowering drugs and are effective at delaying the progression of diabetic and non-diabetic CKD. Ramipril is a prodrug that is being converted in the liver to its active form -Ramiprilat.
The use of Ramipril is beneficial in a broad range of patients who are at a high risk of CV events.